Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: A meta-analysis

Experimental and Therapeutic Medicine

Volumn 4, Issue 5, 2012, Pages 933-937

  Ao, Rui ^a,b   Wang, Yu Hui ^a   Li, Rui Wen ^a   Wang, Zheng Rong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Calcium and magnesium; Chemotherapy; Neurotoxicity; Oxaliplatin

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIPLATIN; PLACEBO;

ACUTE TOXICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC TOXICITY; COCHRANE LIBRARY; COLORECTAL CANCER; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84866427913     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.678     Document Type: Article

References (26)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
2. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
3. Cersosimo RJ: Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39: 128-135, 2005.
4. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F and Lers C: The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406: 25-32, 2000.
5. Gauchan P, Andoh T, Ikeda K, et al: Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull 32: 732-734, 2009.
6. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M and Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85: 2293-2297, 2001.
7. Cascinu S, Catalano V, Cordella L, et al: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trial. J Clin Oncol 16: 3478-3483, 2002.
8. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S and Lersch C: Prevention of oxaliplatin neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr 127: 78-82, 2003.
9. Mariani G, Garrone O, Granetto C, Numico G, LaCiura P and Grecchi G: Oxaliplatin induced neuropathy: could gabapentin be the answer? Proc Am Soc Clin Oncol 19: abs. 2397, 2000.
10. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W and Scheithauer W: Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 12: 421-422, 2001.
11. Agafitei RD, Schneider S, Iqbal S, Yang D, Groshen S and Lenz HJ: Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX). J Clin Oncol 22: 3600, 2004.
12. Muto O, Ando H, Ono T, et al: Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions. Gan To Kagaku Ryoho 34: 579-581, 2007.
13. Gamelin L, Boisdron-Celle M, Delva R, et al: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10: 4055-4061, 2004.
14. Hochster HS, Grothey A and Childs BH: Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25: 4028-4029, 2007.
15. Kurniali PC, Luo LG and Weitberg AB: Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology 24: 289-292, 2010.
16. Khattak MA: Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a tradeoff between drug efficacy and toxicity? Oncologist 16: 1780-1783, 2011.
17. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, 1996.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
19. Grothey A, Nikcevich DA, Sloan JA, et al: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29: 421-427, 2011.
20. Dong M, Xing PY, Liu P, Feng FY and Shi YK: Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity. Zhonghua Zhong Liu Za Zhi 32: 208-211, 2010.
21. Ishibashi K, Okada N, Miyazaki T, Sano M and Ishida H: Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15: 82-87, 2010.
22. Chay WY and Tan SH: Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia-Pacific J Clin Oncol 6: 270-277, 2010.
23. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
24. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxalipatin, fluorouracil, and leucovorin as adjuvant treatment for color cancer. N Engl J Med 350: 2343-2351, 2004.
25. Knijn N, Tol J, Koopman M, et al: The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 47: 369-374, 2011.
26. Gamelin L: Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26: 1189-1190, 2008.